APA (7th ed.) Citation

Nelli, F., Ruggeri, E. M., Schirripa, M., Virtuoso, A., Giannarelli, D., Raso, A., . . . Fabbri, A. Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency. MDPI AG.

Chicago Style (17th ed.) Citation

Nelli, Fabrizio, Enzo Maria Ruggeri, Marta Schirripa, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Daniele Remotti, and Agnese Fabbri. Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency. MDPI AG.

MLA (9th ed.) Citation

Nelli, Fabrizio, et al. Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency. MDPI AG.